Goldman sees two more Fed rate hikes after third hot inflation print
Goldman Sachs expects the Fed to hike in December and January after a third hot core CPI print, then pause.
Goldman Sachs expects the Fed to hike in December and January after a third hot core CPI print, then pause.
Goldman Sachs says chip stocks are near a three-year valuation low despite demand exceeding supply, creating selective buying opportunities.
Goldman's panic gauge saw its biggest two-day swing ever, historically signaling a potential S&P 500 rebound.
Goldman Sachs expects $1.5tn in AI debt over three years, warning supply pressures weigh on credit and spreads.
Goldman Sachs raised its December Brent forecast to $105 a barrel, up 17% from $90, while JPMorgan's model also put Brent below the market.
Goldman Sachs raised its December Brent forecast to $105 a barrel from $90, citing Middle East and Russia-Ukraine supply disruption risks.
Jim Cramer said he'd buy Goldman Sachs after Anthropic filed for an IPO, with the bank set to earn underwriting fees. Markets rose Monday.
Goldman lowered its 12-month Kospi target by 25% to 9,000 but still expects a 60% gain from current levels, arguing the market is pricing in an excessively…
Goldman Sachs says rising bond yields across developed markets signal growing competition for capital, with implications for equities and currencies.
Tech stocks try to rebound; hedge funds reduced positions at decade-fastest pace. Key technical levels for Microsoft, Nvidia, Amazon, Apple outlined.
Goldman Sachs projects S&P 500 earnings of $415 per share by 2027, but cautions that the narrow market breadth leaves recent winners exposed.
Goldman Sachs equity trading jumped 72% to $6.44B in Q3; JPMorgan bond desk missed estimates by over $500M.
Mark Wilson of Goldman Sachs recommends long US megacap tech and German fiscal beneficiaries, citing strong earnings and lower valuations.
Goldman believes European gas prices could overshoot its 70-euro forecast; low storage and falling Mideast LNG exports might push winter TTF near 105 euros.
Goldman Sachs says big pharma is sourcing assets from China biotech as $440 billion in drug patents expire by 2032.